NewcelX Reports Financial Results for 2025 and Provides Shareholders with Update on Accelerated Development of Type 1 Diabetes Treatment in Collaboration with Eledon Pharmaceuticals in 2026
Go back to NewcelX Reports Financial Results for 2025 and Provides Shareholders with Update on Accelerated Development of Type 1 Diabetes Treatment in Collaboration with Eledon Pharmaceuticals in 2026| (NASDAQ: ELDN) | Delayed: 3.74 +0.02 (0.54%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $3.72 | 52 Week High | $ | |||
| Open | $3.84 | 52 Week Low | $ | |||
| Day High | $3.84 | P/E | N/A | |||
| Day Low | $3.62 | EPS | $ | |||
| Volume | 614,382 | |||||
| (NASDAQ: NCEL) | Delayed: 3.80 +0.15 (4.11%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $3.65 | 52 Week High | $ | |||
| Open | $3.70 | 52 Week Low | $ | |||
| Day High | $3.80 | P/E | N/A | |||
| Day Low | $3.66 | EPS | $ | |||
| Volume | 13,053 | |||||
